Assessing the time dependence of prognostic values of cytology and human papillomavirus testing in cervical cancer screening.
Adult
Cervix Uteri
/ pathology
Colposcopy
/ methods
Cytodiagnosis
/ methods
Early Detection of Cancer
/ methods
Female
Genotype
Human papillomavirus 16
/ genetics
Human papillomavirus 18
/ genetics
Humans
Mass Screening
/ methods
Papillomavirus Infections
/ diagnosis
Prognosis
Uterine Cervical Neoplasms
/ diagnosis
Vaginal Smears
/ methods
Uterine Cervical Dysplasia
/ diagnosis
cervical cancer
cytology
genotyping
human papillomavirus
screening
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
15 05 2019
15 05 2019
Historique:
received:
06
04
2018
revised:
04
10
2018
accepted:
16
10
2018
pubmed:
10
11
2018
medline:
7
8
2019
entrez:
10
11
2018
Statut:
ppublish
Résumé
Accurate assessment of risks for developing cervical intraepithelial neoplasia of grade 2 or worse (CIN2+) after a given set of screening test results is instrumental to reaching valid conclusions and informing cervical cancer screening recommendations. Using data from the Canadian Cervical Cancer Screening Trial (CCCaST), we assessed prognostic values of enrollment screening test results to predict CIN2+ among women attending routine cervical screening using multivariable Cox proportional hazards (PH) regression and its flexible extension during each of two follow-up periods (protocol-defined and extended). Nonproportional (time-dependent (TD)) and/or nonlinear effects were modeled, as appropriate. Women with abnormal cytology had hazard ratios (HRs) for CIN2+ detection of 17.61 (95% CI: 11.25-27.57) and 10.46 (95% CI: 5.41-20.24) relative to women with normal cytology during the protocol-defined and extended follow-up periods, respectively. High-risk human papillomavirus (HR-HPV) positivity was an even stronger predictor of CIN2+ risk, with significant TD effects during both follow-up periods (p <0.001 for both TD effects). Risks among women co-testing HR-HPV+ with and without abnormal cytology (relative to women co-testing negative) were highest immediately after baseline, and decreased significantly thereafter (p <0.001 for both TD effects). HRs for HPV16+ and HPV18+ women (relative to those testing HR-HPV-) did not vary significantly over time (HR = 182.96; 95% CI: 95.16-351.77 and HR = 111.81; 95% CI: 44.60-280.31, respectively). Due to TD effects, conventional Cox model estimates considerably underestimated adjusted HRs associated with positive HR-HPV testing results early on in the follow-up periods.
Types de publication
Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
2408-2418Subventions
Organisme : CIHR
ID : CRN-83320
Pays : Canada
Organisme : CIHR
ID : MCT-54063
Pays : Canada
Organisme : CIHR
ID : PJT-148946
Pays : Canada
Informations de copyright
© 2018 UICC.